Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Operating Leases (2020 - 2025)

Aligos Therapeutics filings provide 6 years of Operating Leases readings, the most recent being $1.5 million for Q4 2025.

  • On a quarterly basis, Operating Leases fell 68.2% to $1.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 million, a 68.2% decrease, with the full-year FY2025 number at $1.5 million, down 68.2% from a year prior.
  • Operating Leases hit $1.5 million in Q4 2025 for Aligos Therapeutics, down from $2.4 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $11.3 million in Q4 2021 to a low of $1.5 million in Q4 2025.
  • Median Operating Leases over the past 5 years was $8.5 million (2023), compared with a mean of $7.5 million.
  • Biggest five-year swings in Operating Leases: rose 8.83% in 2021 and later plummeted 68.2% in 2025.
  • Aligos Therapeutics' Operating Leases stood at $11.3 million in 2021, then fell by 18.48% to $9.2 million in 2022, then fell by 16.66% to $7.7 million in 2023, then plummeted by 37.47% to $4.8 million in 2024, then plummeted by 68.2% to $1.5 million in 2025.
  • The last three reported values for Operating Leases were $1.5 million (Q4 2025), $2.4 million (Q3 2025), and $3.2 million (Q2 2025) per Business Quant data.